A Food and Drug Administration advisory committee voted 16-1 Thursday that the benefits of Paxlovid outweigh its risks for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, moving Pfizer’s five-day oral antiviral regimen closer to full FDA approval after more than a year of use under emergency authorization.

The FDA’s March 16 meeting record identifies the application as New Drug Application 217188 for nirmatrelvir and ritonavir co-packaged tablets. The committee’s recommendation is not binding, but it gives the agency an external assessment of the evidence as FDA completes its own review of Pfizer’s application.

A treatment first authorized during the Delta-to-Omicron transition

Paxlovid entered U.S. practice under an emergency use authorization issued in December 2021. The FDA’s original authorization made the drug available to eligible adults and adolescents age 12 and older who weigh at least 40 kilograms, have mild-to-moderate COVID-19 and face high risk of hospitalization or death. Treatment is intended to begin as soon as possible after diagnosis and within five days of symptom onset.

The regimen combines nirmatrelvir, which inhibits a SARS-CoV-2 protease needed for viral replication, with ritonavir, which slows the metabolism of nirmatrelvir so effective concentrations persist in the body. Patients take the drugs twice daily for five days. That pharmacologic design is central to the treatment’s efficacy, but ritonavir’s effects on drug metabolism are also the source of the most important prescribing complication.

Pfizer submitted its full-approval application in June 2022. The company said the filing sought approval for high-risk patients and included longer-term follow-up from its clinical development program. Thursday’s committee meeting therefore examined a treatment already used extensively in practice but still operating under the legal framework of emergency authorization.

Randomized trial established a large benefit in unvaccinated high-risk adults

The foundational efficacy evidence comes from EPIC-HR, a randomized, double-blind, placebo-controlled trial in nonhospitalized, symptomatic, unvaccinated adults at high risk for severe COVID-19. The peer-reviewed New England Journal of Medicine report found a substantial reduction in hospitalization or death when nirmatrelvir-ritonavir was started early in the course of illness.

The FDA’s 2021 authorization analysis reported that among patients treated within five days of symptom onset, 0.8% of Paxlovid recipients were hospitalized or died during 28 days of follow-up, compared with 6.0% in the placebo group, an approximately 88% relative reduction. The trial occurred before today’s much higher levels of vaccination, prior infection and Omicron circulation, so one of the advisory committee’s central questions was how strongly those original results translate to the population now seeking treatment.

Pfizer’s March 16 committee-vote announcement said the panel concluded that the available data support Paxlovid’s safety and effectiveness for high-risk adults. Committee members emphasized that the magnitude of benefit depends on a patient’s baseline risk: an older or immunocompromised adult with multiple risk factors has more to gain from preventing hospitalization than a young, otherwise healthy patient who already has substantial immunity.

Rebound data ease one concern but do not eliminate follow-up needs

Reports of recurrent symptoms or renewed positive tests after completion of Paxlovid have drawn significant attention since the drug’s rollout. The Centers for Disease Control and Prevention issued a May 2022 Health Alert describing “COVID-19 rebound” as a recurrence of symptoms or a new positive viral test after initial recovery, typically two to eight days later. CDC said at the time that Paxlovid remained recommended for eligible high-risk patients and that reported rebound cases had generally been mild.

By this week, the evidence presented to the FDA committee was more reassuring about causation. Analyses of clinical-trial data found rebound in both Paxlovid and placebo groups rather than a clear excess attributable to the drug. A contemporaneous Reuters report on Thursday’s vote said panel members were reassured by the rebound data while still recognizing the phenomenon as clinically relevant for patients who may again test positive or experience symptoms after finishing treatment.

That distinction matters. The committee was not deciding whether rebound exists; it was weighing whether Paxlovid itself creates enough additional rebound risk to undermine its benefit in high-risk patients. Available evidence did not establish such a relationship, and rebound has also been observed in untreated infection.

Drug-drug interactions remain the central safety problem

The harder safety issue is ritonavir’s interaction with other medications. Ritonavir strongly affects the CYP3A metabolic pathway, and coadministration with certain drugs can raise their concentrations to dangerous levels or, in other combinations, reduce effective antiviral exposure. The original FDA authorization therefore included contraindications and detailed instructions for medication review, dose adjustment and temporary interruption of interacting therapies.

This is especially important because many patients at highest risk from COVID-19 are older adults with cardiovascular disease, diabetes, kidney disease, immune suppression or other chronic conditions and may take multiple prescriptions. The advisory committee discussion emphasized that the benefit-risk calculation can change if clinically important interactions are not recognized and managed.

A contemporaneous CNN report from the meeting noted FDA estimates that more than half of Paxlovid-eligible patients may be taking at least one medication with a potential interaction at the time of diagnosis. Committee members stressed careful medication reconciliation and, where appropriate, temporary withholding, dose adjustment, alternative therapy or enhanced monitoring.

Full approval would formalize a treatment already central to outpatient care

The committee’s vote does not itself convert Paxlovid from emergency authorization to an approved drug. FDA must finish reviewing the application and decide whether the evidence satisfies the statutory standard for approval. Pfizer said the agency’s target action date is in May. The existing emergency authorization remains the operative framework in the meantime, including authorized use in eligible adolescents even though the application discussed Thursday focuses on adults.

The decision comes as the treatment landscape has narrowed. Several monoclonal antibodies have lost authorization because circulating variants became resistant, leaving oral antivirals with a larger role for high-risk outpatients. Paxlovid can be taken at home and has a short treatment window, making rapid diagnosis, prescribing and medication review essential.

The 16-1 vote reflects a judgment that, for adults truly at high risk of severe COVID-19, the prevention of hospitalization and death remains more important than the manageable risks identified so far. It also makes clear that Paxlovid is not a one-size-fits-all prescription. The strongest evidence supports targeted use in patients with meaningful baseline risk, started promptly and accompanied by careful review of kidney function, liver status and interacting drugs.

More than a year after emergency authorization, the clinical question has shifted. Physicians are no longer asking whether Paxlovid can work under tightly controlled trial conditions; they are deciding which patients in a highly immune, Omicron-era population stand to benefit most. Thursday’s advisory vote supports keeping the antiviral at the center of that strategy while putting medication safety and individualized risk assessment squarely alongside efficacy.